Leeward Investments LLC MA Has $9.32 Million Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Leeward Investments LLC MA lessened its position in Option Care Health, Inc. (NASDAQ:OPCH) by 7.2% during the 4th quarter, Holdings Channel reports. The firm owned 401,629 shares of the company’s stock after selling 31,283 shares during the quarter. Leeward Investments LLC MA’s holdings in Option Care Health were worth $9,318,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. UMB Bank n.a. boosted its stake in shares of Option Care Health by 41.7% in the 4th quarter. UMB Bank n.a. now owns 1,176 shares of the company’s stock valued at $27,000 after purchasing an additional 346 shares in the last quarter. International Assets Investment Management LLC boosted its stake in shares of Option Care Health by 3,029.7% in the 3rd quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock valued at $91,000 after purchasing an additional 2,757 shares in the last quarter. Quarry LP lifted its position in Option Care Health by 327.7% during the 3rd quarter. Quarry LP now owns 3,430 shares of the company’s stock worth $107,000 after buying an additional 2,628 shares in the last quarter. Blue Trust Inc. lifted its position in Option Care Health by 16.9% during the 4th quarter. Blue Trust Inc. now owns 4,703 shares of the company’s stock worth $109,000 after buying an additional 681 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its position in Option Care Health by 2,621.3% during the 4th quarter. Venturi Wealth Management LLC now owns 4,735 shares of the company’s stock worth $110,000 after buying an additional 4,561 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on OPCH. Truist Financial reduced their price target on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. JMP Securities reiterated a “market outperform” rating and set a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. JPMorgan Chase & Co. upped their price target on shares of Option Care Health from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Barrington Research upped their price target on shares of Option Care Health from $32.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 14th. Finally, Bank of America upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and upped their price target for the stock from $26.00 to $33.00 in a research report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.25.

Option Care Health Stock Performance

Shares of NASDAQ:OPCH opened at $32.00 on Friday. The stock has a market capitalization of $5.45 billion, a P/E ratio of 26.89, a P/E/G ratio of 2.30 and a beta of 1.35. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $34.63. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The business has a 50-day moving average price of $27.71 and a two-hundred day moving average price of $27.98.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.